Avacta Group plc (AVCT) Ordinary Shares 10p
6.70p
(10.50%)
- Add to watchlist
- Create an alert
- This stock can be held in a
6.70p
(10.50%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
6.70p
(10.50%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
64.50p
72.00p
74.00p
£287.83 million
63.80p
64.00p
27.25p
n/a
0.30p (0.47%) Previous:
0.30p
4,648,093
n/a
20,000
Performance
| 1 week 1W | 7.54% | 1 year 1Y | 10% |
|---|---|---|---|
| 1 month 1M | 20.38% | 2 years 2Y | 52.39% |
| 3 months 3M | 57.53% | 3 years 3Y | 37.14% |
| 6 months 6M | 105.81% | 5 years 5Y | 63.75% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Fundamental data
| Year ending: | 31/12/2024 | 31/12/2023 |
|---|---|---|
| Revenue (£m) | 0.11 | 2.85 |
| Profit before tax (£m) | (28.98) | (31.12) |
| Adjusted EPS (p): | (8.54) | (10.69) |
| P/E ratio | n/a | n/a |
| PEG | n/a | n/a |
| EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: British pound
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Avacta presents promising findings to Boston conference
27 October 2025 09:07
-
Avacta raises £16m, releases solid clinical trial data
20 October 2025 09:01
-
Avacta reports continued progress in second quarter
2 July 2025 11:03
-
Avacta presents preclinical data at AACR-NCI-EORTC
27 October 2025 07:00
-
Equity fundraise of £16 million
20 October 2025 07:01
-
Avacta Presents Phase 1a Data for Faridoxorubicin
20 October 2025 07:00
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.